Download
1 / 2
20 likes | 36 Views
Opdyta belongs to a group of cancer drugs known as monoclonal antibodies. <br>Opdyta is also known as an immune checkpoint inhibitor. Sometimes these drugs are called targeted therapies because they target specific proteins (receptors) on the surface of cells.
E N D
OPDYTA 40MG-100MG Description Nivolumab is a generic form of brand name Opdyta which is a targeted therapy drug presently used to cure from melanoma, non-small cell lung cancer or kidney (renal cell) cancer. Opdyta belongs to a group of cancer drugs known as monoclonal antibodies. Opdyta is also known as an immune checkpoint inhibitor. Sometimes these drugs are called targeted therapies because they target specific proteins (receptors) on the surface of cells. Indication Opdyta is indicated for the treatment of patients having conditions like : • Melanoma which has spread or can’t be removed with surgery • chemotherapy Non-Small Cell Lung Cancer which has spread or come back after • Kidney (Renal Cell) Cancer which has come back after chemotherapy Mechanism Of Action Opdyta stops the moleculeactivity called PD-1, and it is a protein whichinhibits T cells from identifying and attacking inflamed tissues and cancer cells. PD-1 can trick the immune system into overlooking melanoma cells as normal cells. Opdyta triggers your immune system’s reacting to melanoma by inhibiting the PD-1 protein on T cells. The drug activates T cells so which they can attack melanoma cells anywhere in your body. Dosage and administration Opdyta recommended dosage for unresectable or metastatic melanoma : As single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity
With ipilimumab. The recommended dose of Opdyta is 1mg/kg administrated as an intravenous infusion over 30 minutes, followed by ipilimumab 3mg/kg given as IV over 90 minutes on the same day. Duration 3 weeks of max 4 doses, after completing combination dose continue the single agent treatment For adjuvant treatment of melanoma : As single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity for up to 1 year. For Non-small cell lung cancer : As single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity. For small cell lung cancer : As single agent is either 240mg every 2 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity for up to 1 year. Lactation Opdyta Excretion in human breast milk is not known; advise women to discontinue breastfeeding during treatment Storage Store at under refrigeration at 2°C to 8°C. Missed Dose If you missed a dose take it as soon as possible, if time reach for next dose, then skip missed dose and continue regular schedule. Avoid taking two doses at a time. Avoid taking missed dose within 12hrs of the next dose.
